Back to Freepaper Session
Subconjunctival bevacizumab injection for ocular surface squamous neoplasia
Session Title: Cornea Medical
Session Date/Time: Monday 07/10/2013 | 08:00-10:00
Paper Time: 08:56
Venue: Elicium 1 (First Floor)
First Author: : A.Faramarzi IRAN
Co Author(s): : H. Faghihi
To determine the efficacy and safety of perilesional/subconjunctival bevacizumab injections for the management of ocular surface squamous neoplasia (OSSN).
Interventional case series
Ten eyes of 10 patients with an OSSN diagnosis confirmed by impression cytology received two perilesional/subconjunctival injections of bevacizumab at a two week interval. Patients were evaluated for three months, during which time changes in the lesions were documented using digital photography. After this period, excisional biopsy of the remaining tumor and cryotherapy of the conjunctival borders were performed if deemed necessary.
The mean age of the patients was 65±12 years (±SD). All of the tumors were nasal in origin and had varying degrees of vascularization. The mean lesion area before treatment was 16±6.9 mm2. Two weeks after the first injection, the mean reduction observed in the tumor area was 25±5.65% and ranged from 17 to 33% (P=0.001). Two weeks after the second injection, the mean tumor area was further decreased (42±33%, ranging from 15 to 100 %, P=0.049). Corneal extension of the tumor was not affected significantly in eight of the eyes with concomitant conjunctival and corneal involvements. Complete disappearance of the tumor was demonstrated by impression cytology and occurred in two cases involving lesions clinically confined to the conjunctiva. No systemic or ocular side effects occurred during the study period.
Perilesional/subconjuctival injections of bevacizumab decrease the size and vascularity of OSSN and may be curative in lesions limited to the conjunctiva. However, this treatment has no significant effect on the corneal extension of OSSN.